Join Growin Stock Community!

Liminatus pharma, inc. class a common stockLIMN.US Overview

US StockHealthcare
(No presentation for LIMN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

LIMN AI Insights

LIMN Overall Performance

LIMN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

LIMN Recent Performance

-3.12%

Liminatus pharma, inc. class a common stock

0.05%

Avg of Sector

-0.31%

S&P500

LIMN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

LIMN Key Information

LIMN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

LIMN Profile

Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.

Price of LIMN

LIMN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

LIMN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.09
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.09
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is LIMN's latest earnings report released?

    The most recent financial report for Liminatus pharma, inc. class a common stock (LIMN) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating LIMN's short-term business performance and financial health. For the latest updates on LIMN's earnings releases, visit this page regularly.

  • How much cash does LIMN have?

    At the end of the period, Liminatus pharma, inc. class a common stock (LIMN) held Total Cash and Cash Equivalents of 724.5K, accounting for 0.54 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is LIMN's EPS continuing to grow?

    According to the past four quarterly reports, Liminatus pharma, inc. class a common stock (LIMN)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.07. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of LIMN?

    Liminatus pharma, inc. class a common stock (LIMN)'s Free Cash Flow (FCF) for the period is -613.72K, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 15.85% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of LIMN?

    The latest valuation data shows Liminatus pharma, inc. class a common stock (LIMN) has a Price-To-Earnings (PE) ratio of -6.18 and a Price/Earnings-To-Growth (PEG) ratio of 0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.